Phaseline

Companies › Bioray Laboratories

Bioray Laboratories: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Hematology, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BRL-201
CD19-targeted CAR-T cell therapy with PD-1 site-specific integration
CD19Phase 1Non-hodgkin Lymphoma,B CellNov 2026
BRL-101
CRISPR-Cas9 modified autologous CD34+ hematopoietic stem and progenitor cells with BCL11A
–Phase 1Beta-ThalassemiaJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05741359BRL-201Phase 1Non-hodgkin Lymphoma,B CellOncologyNov 2026
NCT05577312BRL-101Phase 1Beta-ThalassemiaHematologyJul 2027

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.